Pasar al contenido principal

CELULAS CAR-T FRENTE A ANTIGENOS DEL MICROAMBIENTE TUMORAL COMO ALTERNATIVA PARA EL TRATAMIENTO DE TUMORES SOLIDOS

PID2021-128283OA-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2021
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACION PARA LA INVESTIGACION MEDICA APLICADA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Preclinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myeloma

  • Larrayoz, Marta
  • García-Barcina, María
  • Celay, Jon
  • Etxebeste, Amaia
  • Jimenez, Maddalen
  • Perez, Cristina
  • Ordoñez, Raquel
  • Cobaleda, Cesar
  • Botta, Cirino
  • Fresquet, Vicente
  • Roa, Sergio
  • Goicoechea, Ibai
  • Maia, Catarina
  • Lasaga, Miren
  • Chesi, Marta
  • Bergsagel, P Leif
  • Larrayoz, Maria J
  • Calasanz, Maria J
  • Campos-Sanchez, Elena
  • Martinez-Cano, Jorge
  • Panizo, Carlos
  • Rodriguez-Otero, Paula
  • Vicent, Silvestre
  • Roncador, Giovanna
  • Gonzalez, Patricia
  • Takahashi, Satoru
  • Katz, Samuel G
  • Walensky, Loren D
  • Ruppert, Shannon M
  • Lasater, Elisabeth A
  • Amann, Maria
  • Lozano, Teresa
  • Llopiz, Diana
  • Sarobe, Pablo
  • Lasarte, Juan J
  • Planell, Nuria
  • Gomez-Cabrero, David
  • Kudryashova, Olga
  • Kurilovich, Anna
  • Revuelta, Maria V
  • Cerchietti, Leandro
  • Agirre, Xabier
  • San Miguel, Jesus
  • Paiva, Bruno
  • Prosper, Felipe
  • Martinez-Climent, Jose A
The historical lack of preclinical models reflecting the genetic heterogeneity of multiple myeloma (MM) hampers the advance of therapeutic discoveries. To circumvent this limitation, we screened mice engineered to carry eight MM lesions (NF-κB, KRAS, MYC, TP53, BCL2, cyclin D1, MMSET/NSD2 and c-MAF) combinatorially activated in B lymphocytes following T cell-driven immunization. Fifteen genetically diverse models developed bone marrow (BM) tumors fulfilling MM pathogenesis. Integrative analyses of ∼500 mice and ∼1,000 patients revealed a common MAPK–MYC genetic pathway that accelerated time to progression from precursor states across genetically heterogeneous MM. MYC-dependent time to progression conditioned immune evasion mechanisms that remodeled the BM microenvironment differently. Rapid MYC-driven progressors exhibited a high number of activated/exhausted CD8 T cells with reduced immunosuppressive regulatory T (T) cells, while late MYC acquisition in slow progressors was associated with lower CD8 T cell infiltration and more abundant T cells. Single-cell transcriptomics and functional assays defined a high ratio of CD8 T cells versus T cells as a predictor of response to immune checkpoint blockade (ICB). In clinical series, high CD8 T/T cell ratios underlie early progression in untreated smoldering MM, and correlated with early relapse in newly diagnosed patients with MM under Len/Dex therap, This work was supported by the imCORE Network on behalf of F. Hoffmann-La Roche (NAV4 and NAV15 projects). Additional support was obtained from Spanish Ministry of Health - Instituto de Salud Carlos III (FIS), grants PI19/00818, PI20/00048, PI20/00260, CIBERONC no. CB16/12/00489 and no. CB16/12/00369, with support from FEDER (Fondo Europeo de Desarrollo Regional); Paula and Rodger Riney Foundation; Accelerator Award Program from the Spanish Association Against Cancer (AECC), Cancer Research United Kingdom (CRUK), and Associazione Italiana per la Ricerca sul Cancro (AIRC); Spanish Ministry of Education and Science, grants SAF2017-83061-R, PLEC2021-008094, and PID2021-128283OA; Fundacion Arnal Planelles; Fundacion Ramon Areces; Banco de Santander; European Research Council Starting Grant (MYELOMANEXT); CRIS Cancer Foundation (PR_EX_2020-02); AICR grant 24534, 2021; and Leukemia Lymphoma Society. M.C. and P.L.B. were supported by RO1 CA234181. L.C. was supported by R01 CA242069. M.L. was supported by a junior investigator grant from AECC. M.J.G.-B. was supported by Fundacion Arnal Planelles. J.C. was supported by AECC through the ‘Accelerator’ Award. S.R. was supported by RYC-2014-16399/MEC. J.M.C. is the recipient of an FPU fellowship from Universidad Autonoma de Madrid.
Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publicación Artículo científico (JournalArticle)

Improvement of cognitive function in wild-type and Alzheimer's disease mouse models by the immunomodulatory properties of menthol inhalation or by depletion of T regulatory cells

  • Casares, Noelia
  • Alfaro Larraya, María
  • Cuadrado-Tejedor, Mar
  • Lasarte-Cía, Aritz
  • Navarro Negredo, Flor
  • Vivas, Isabel
  • Espelosín, María
  • Cartas Cejudo, Paz
  • Fernández Irigoyen, Joaquín
  • Santamaría Martínez, Enrique
  • García-Osta, Ana
  • Lasarte, Juan José
A complex network of interactions exists between the olfactory, immune and central nervous systems. In this work we intend to investigate this connection through the use of an immunostimulatory odorant like menthol, analyzing its impact on the immune system and the cognitive capacity in healthy and Alzheimer’s Disease Mouse Models. We first found that repeated short exposures to menthol odor enhanced the immune response against ovalbumin immunization. Menthol inhalation also improved the cognitive capacity of immunocompetent mice but not in immunodeficient NSG mice, which exhibited very poor fear-conditioning. This improvement was associated with a downregulation of IL-1β and IL-6 mRNA in the brain´s prefrontal cortex, and it was impaired by anosmia induction with methimazole. Exposure to menthol for 6 months (1 week per month) prevented the cognitive impairment observed in the APP/PS1 mouse model of Alzheimer. Besides, this improvement was also observed by the depletion or inhibition of T regulatory cells. Treg depletion also improved the cognitive capacity of the APPNL-G-F/NL-G-F Alzheimer´s mouse model. In all cases, the improvement in learning capacity was associated with a downregulation of IL-1β mRNA. Blockade of the IL-1 receptor with anakinra resulted in a significant increase in cognitive capacity in healthy mice as well as in the APP/PS1 model of Alzheimer´s disease. These data suggest an association between the immunomodulatory capacity of smells and their impact on the cognitive functions of the animals, highlighting the potential of odors and immune modulators as therapeutic agents for CNS-related diseases., This work was supported by a grant from the Ministry of Science and Innovation (PID2021-128283OA-I00 financed by MCIN/ AEI /10.13039/501100011033 and by FEDER A way of making Europe and PID2019-104921RB-I00), Department of Economic and Business Development from the Government of Navarra (INNOLFACT project; Ref. 0011-1411-2020-000028) and Explora grant from Ministry of Economy and Competitiveness, (SAF2013-50067-EXP to JL).